Tech Company Financing Transactions
Soligenix Funding Round
Soligenix closed a $5.9 million financing round on 7/2/2010. Investors included private investors.
Transaction Overview
Company Name
Announced On
7/2/2010
Transaction Type
Venture Equity
Amount
$5,904,277
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
29 Emmons Dr. B-10
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Website
Email Address
Not Recorded
Overview
Soligenix, Inc. (OTCQB: SNGX) is a late-stage biopharmaceutical company committed to the development of life-saving therapeutics and vaccines. Soligenix has two areas of focus: 1) a therapeutics platform and 2) a biodefense platform to develop vaccines for military and civilian applications.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Christopher Schaber
Chief Financial Officer
Karen Krumeich
Chief Medical Officer
Richard Straube
Chief Scientific Officer
Oreola Donini
Vice President
Christopher Cavalli
VP - Regulatory Affairs
Adam Rumage
Browse more venture capital transactions:
Prev: 7/1/2010: Ingenuity Systems venture capital transaction
Next: 7/2/2010: DiVitas Networks venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs